Indo-Bangla Pharmaceuticals Limited
Nature of business
|
The Company is engaged in manufacturing and selling of all kinds of
medicine (excluding Antibiotic), medical preparations drugs &
chemicals (Human Health). The Company applied for permission for
production and selling of veterinary medicine also
|
Reason for IPO
|
Construction and other civil works 58,580,000 (29.29%)
Machineries 124,720,000(62.36%)
IPO expenses 16,700,000 (08.35%)
Total 200,000,000 (100.00%)
|
Subscription open
|
08 Apr 2018
|
Subscription close
|
18 Apr 2018
|
Subscription close for NRB
|
08 Apr 2018
to 18 Apr 2018
|
Offer price
|
Tk. 10.0
|
Face value per share
|
Tk. 10.0
|
Market lot
|
500 units
|
Single lot price
|
Tk. 5000.0
|
EPS
|
Tk. 1.21 for the period ended on June 30, 2017
|
NAV
|
Tk. 12.84 as at June 30, 2017
|
Public offer
|
|
Major product
|
Indo-Bangla Pharmaceuticals Ltd. produces a good number of
products of Human products division. All the products of IndoBangla
Pharmaceuticals Ltd. categorized under Non Biological
Products and Biological Products.
|
Issue Manager
|
1. AFC Capital Limited 2. EBL Investments Limited 3. CAPM Advisory Limited
|
Website
|
http://www.indo-banglapharma.com
|